Business
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors. Having been in the pharmaceutical industry for more than 20 years, Dr. Martell currently serves as Head of Research and Development, as well as previously serving on the Board of Directors for more than six years at Curis, Inc. He is also an attending physician at Tufts Medical Center in Boston. Previously, he has held management positions in numerous publicly traded and private companies, including Epi-Cure Pharmaceuticals, Tesaro, Inc., and Methylgene, Inc., as well as filling key roles at Big Pharma, including Bayer and Bristol-Meyers Squibb. In addition, he served in multiple other top-tier academic hospitals, including Duke University, where he completed his internal medicine residency and oncology fellowship, as well as serving as an Assistant Professor and a Fellow in the Center for the Study of Aging and Human Development. He also served as adjunct Assistant Clinical Professor at Yale. Dr. Martell is widely published with an impressive array of articles in peer-reviewed medical journals. He received his medical training at Wayne State University School of Medicine, a Ph.D. in pharmacology from the University of Michigan and his Bachelor of Arts degree in chemistry from Kalamazoo College. “Robert’s extensive industry experience and deep understanding of the issues associated with drug development, combined with his ongoing practice makes him an ideal board member for Indaptus. I look forward to collaborating with him to help guide the Company toward continued success,” stated Roger Pomerantz, M.D., chairman of Indaptus Therapeutics’ Board of Directors. “As a practicing physician with deep oncology experience, and a long-time veteran of the pharmaceutical industry, we believe Robert is an ideal addition to our Board of Directors,” commented Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer. “As a clinical-stage company, we look forward to his input in our development programs and his perspective as we continue to explore our Decoy platform toward what we believe will be a novel approach to treating cancer.” Ab...